A monoclonal antibody that blocks interleukin 15 has been shown to reduce intestinal inflammation and improve clinical symptoms induced by gluten consumption in celiac disease. PRV-015 may be effective as an adjunctive treatment to a GFD in NRCD patients.
What we need:
Subjects 18-70 years old
Must be diagnosed with Celiac disease by intestinal biopsy at least 12 months prior
Subjects have followed (or attempted to follow) a gluten free diet 12 months prior, and willing to maintain a gluten free diet for study duration
Have at least one of the following symptoms
Diarrhea
Loose Stools
Abdominal pain
Cramping
Bloating/gas
What we cannot have:
Have current diagnosis of severe complications (celiac disease)
Diagnosis of any chronic or active GI disease
Presence of infection with flu like symptoms
Active GI infection, including H. Pylori
History of TB
